Format

Send to

Choose Destination
Expert Opin Ther Targets. 2014 Mar;18(3):257-68. doi: 10.1517/14728222.2014.863876. Epub 2014 Jan 6.

Targeting HMGB1 in the treatment of sepsis.

Author information

1
The Feinstein Institute for Medical Research and North Shore University Hospital, The Hofstra North Shore - LIJ School of Medicine, Laboratory of Emergency Medicine, North Shore-LIJ Health System , 350 Community Drive, Manhasset, NY 11030 , USA +1 516 562 2823 ; +1 516 562 1022 ; hwang@nshs.edu.

Abstract

INTRODUCTION:

Sepsis refers to the host's deleterious and non-resolving systemic inflammatory response to microbial infections and represents the leading cause of death in the intensive care unit. The pathogenesis of sepsis is complex, but partly mediated by a newly identified alarmin molecule, the high mobility group box 1 (HMGB1).

AREAS COVERED:

Here we review the evidence that support extracellular HMGB1 as a late mediator of experimental sepsis with a wider therapeutic window and discuss the therapeutic potential of HMGB1-neutralizing antibodies and small molecule inhibitors (herbal components) in experimental sepsis.

EXPERT OPINION:

It will be important to evaluate the efficacy of HMGB1-targeting strategies for the clinical management of human sepsis in the future.

PMID:
24392842
PMCID:
PMC3945414
DOI:
10.1517/14728222.2014.863876
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center